Liaoning University of Traditional Chinese Medicine

About: Liaoning University of Traditional Chinese Medicine is a education organization based out in Shenyang, China. It is known for research contribution in the topics: Randomized controlled trial & Acupuncture. The organization has 2040 authors who have published 1326 publications receiving 14664 citations.

Efficacy and safety of Re-Du-Ning injection in the treatment of seasonal influenza: results from a randomized, double-blinded, multicenter, oseltamivir-controlled trial

Abstract: // Yu Liu 1, 2 , Wei Mu 2 , Wei Xiao 3 , Bao-Lin Wei 2 , Lan Wang 4 , Xin-Qiao Liu 5 , Xu-Dong Xiong 6 , Xiao-Min Huang 7 , Ye-Qing Zhang 8 , Hai-Ming Chen 9 , Feng-Jie Yan 10 , Yu-Ping Tan 11 and Yu-Hong Huang 2 1 Shenzhen Traditional Chinese Medicine Hospital Affiliated to Guangzhou University of Traditional Chinese Medicine, Shenzhen 518033, China 2 The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China 3 State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu 222001, China 4 Dongzhimen Hospital Affiliated to Beijing University of Traditional Chinese Medicine, Beijing 100007, China 5 The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China 6 Shanghai ShuGuang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China 7 Zhejiang Hospital of Traditional Chinese Medicine, Hangzhou 310006, China 8 Jiangsu Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing 210028, China 9 Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110032, China 10 Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun 130021, China 11 Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China Correspondence to: Yu-Hong Huang, email: hyh101@126.com Keywords: Re-Du-Ning injection, seasonal influenza, oseltamivir, clinical trial Received: March 29, 2017 Accepted: June 24, 2017 Published: July 13, 2017 ABSTRACT Objective: To assess the efficacy and safety of RDNI in the treatment of seasonal influenza. Results: 1575 participants were screened and 229 completed the study and had a RT-PCR laboratory confirmation of influenza virus infection. Fever alleviation time was 2 and 6 hours, and fever clearance time was 27 and 47 in RDNI and oseltamivir, with significant difference between two groups. Total scores of influenza symptoms descended more in RDNI than oseltamivir on day 2 and day 3. Single symptom such as fever, aversion to cold, sore throat and nasal obstruction score descended more in RDNI than oseltamivir on different days. 20 subjects used aspirin during the trial, and there was no significant difference between two groups. Materials and Methods: We conducted a randomized, double-blind, double-dummy, oseltamivir controlled clinical trial. Patients with a positive influenza rapid test diagnosis were enrolled and randomized to receive RDNI or oseltamivir. Primary outcome was the median fever alleviation and clearance time. Secondary outcomes were total 8 influenza symptom scores, the single influenza symptom score, and the frequency of aspirin usage. Conclusions: The effect of RDNI was not worse than oseltamivir on the alleviation of influenza symptoms. RDNI was well tolerated, with no serious adverse events noted during the study period.

The estrogen‑like protective effect of Lycium barbarum polysaccharides in reducing oxidative stress on myocardial cells from ovariectomized rats

Abstract: Previous studies have demonstrated that ovariectomy may lead to a reduction in antioxidative biomarkers in the myocardium, thus suggesting that estrogens may serve a protective role in the suppression of oxidative stress. Lycium barbarum polysaccharides (LBP) are a well‑known antioxidant Chinese traditional medicine, which appear to have a similar function to estrogens with regards to the regulation of cardiac function. In the present study, 30 Sprague‑Dawley rats were randomly divided into the following groups: Sham operation group, ovariectomized (OVX) group, estradiol valerate group, high‑dose LBP (LBP‑H) group and low‑dose LBP (LBP‑L) group. All of the rats were provided tap water, estradiol valerate or LBP for 12 weeks. In addition, all rats were ovariectomized, with the exception of rats in the sham operation group, which underwent fat removal only. Reactive oxygen species (ROS), malondialdehyde (MDA), glutathione peroxidase (GSH‑px), catalase (CAT) and superoxide dismutase activities were subsequently examined. The protein expression levels of cleaved caspase‑9, cleaved caspase‑3 and phosphorylated‑protein kinase B (p‑Akt) were also assessed. The results demonstrated that high‑dose LBP decreased the enhanced levels of ROS and MDA in OVX rats, whereas GSH‑px and CAT activities were increased in the LBP‑H group compared with in OVX rats. Furthermore, the expression levels of cleaved caspase‑9 and cleaved caspase‑3 were significantly upregulated in the OVX group, whereas high‑dose LBP exerted protective effects on OVX rats by decreasing the expression of apoptotic proteins. Conversely, p‑Akt expression was decreased in the OVX group and was increased in the LBP‑H group. These results indicated that LBP is essentially involved in cardiac protection by inhibiting apoptosis in response to oxidative stress. In addition, improvement of antioxidant status by LBP is associated with the Akt signaling pathway in the myocardium of OVX rats.

Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors.

Abstract: Novel series of 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylates (5a-p, 7, and 8a-e) were synthesized and evaluated for their antiproliferative activity against the A549, HT29, H460, and H1975 cancer cell lines in vitro. Nine compounds (5a-c, 5i, 5j, 7, 8a, 8b, 8i) demonstrated moderate to significant cytotoxic activity with IC50 values below 18 µM on A549 cells, which were comparable to that of the reference gefitinib (IC50 = 18.44 µM). Especially, the further enzymatic analysis on epidermal growth factor receptor (EGFR), HER2, and VEGFR identified compound 5a as a promising hit that exhibited considerable potency both in cellular (IC50 = 5.67, 17.04, 11.29, and 12.65 µM, respectively) and EGFR enzymatic assays (IC50 = 14.8 nM). Compound 5a was capable of down-regulating the expression of EGFR and inhibited EGFR phosphorylation in a dose-dependent manner, representing a potential EGFR candidate for further optimization.

Effects of Chinese Herbal Compound "Xuemai Ning"on Rabbit Atherosclerosis Model and Expression of ABCA1.

Abstract: Objective: To observe the lipid and the pathological changes of carotid artery smooth muscle cells in atherosclerotic rabbits, verification of Chinese herbal compound which has improve blood lipid and anti atherosclerosis effects, focus on ABCA1 as the key receptor which participated in reverse cholesterol transport, to study the mechanism of Chinese herbal compound (Xuemai Ning).